Original Article
Identification of genes associated with SiHa cell sensitivity to paclitaxel by CRISPR-Cas9 knockout screening

Wei Wei, Yue He, Yu-Mei Wu

Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China

Received January 18, 2018; Accepted February 22, 2018; Epub April 1, 2018; Published April 15, 2018

Abstract: Although chemotherapy has significantly improved the prognosis of patients with cervical cancer, many patients exhibit selective responses to chemotherapy. This study aimed to identify genes associated with the sensitivity of cervical cancer cells to paclitaxel. SiHa cells were transfected with lentiCRISPR (genome-scale CRISPR knockout library v.2) and then treated with paclitaxel or vehicle for 14 days. Subsequently, we screened for candidate genes whose loss resulted in sensitivity to paclitaxel. We obtained 374 candidates, some of which were consistent with those reported in previous studies, including ABCC9, IL37, EIF3C, AKT1S1, and several members of the PPP gene family (PPP1R7, PPP2R5B, PPP1R7, and PPP1R11). Importantly, our findings highlighted the newly identified genes that could provide novel insights into the mechanisms of paclitaxel sensitivity in cervical cancer. Cas9 technology provides a reliable method for the exploration of more effective combination chemotherapies for patients at the gene level.

Keywords: Paclitaxel sensitivity, cervical cancer, CRISPR-Cas9 technology

Introduction

Cervical cancer is the second most common cancer in women worldwide [1]. The primary therapeutic options include surgery, radiotherapy, and chemotherapy. However, these methods cannot always prevent metastasis and recurrence of cancer, thereby affecting the prognosis. One of the primary causes of treatment failure is poor chemotherapy sensitivity. Chemotherapy is also important in patients after surgery, particularly in those who show risk factors for tumor recurrence and metastasis [2, 3]. Moreover, neoadjuvant chemotherapy has been applied to patients with locally advanced cervical cancer to improve surgical outcomes [4]. However, many patients exhibit selective responses to chemotherapy.

In patients with cervical cancer, paclitaxel (PTX) is a commonly used chemotherapeutic agent [5], and the mechanisms affecting PTX sensitivity in cervical cancer have been studied. Tissue culture studies have consistently shown that ABCC1 and ABCG2, belonging to the ABC family, are involved in reduce the sensitivity of multidrug chemotherapy, including that to PTX [6-9]. Zhang reported that nuclear localization of β-catenin is associated with chemotherapy sensitivity in human cervical squamous cell carcinoma [10], and several studies have described the roles of apoptosis-associated proteins (Bax, Bad, and the BCL family) in PTX therapeutic effect [11].

Although mechanisms mediating chemosensitivity in cervical cancer have been extensively studied, they are still poorly understood. Therefore, this study aimed to systematically screen genes related to PTX sensitivity using a genome-scale CRISPR-Cas9 screen in human SiHa cells.

Materials and methods

Cell culture

SiHa cells were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (HyClone, Logan, UT, USA). Cells were incubated at 37°C with 5% CO₂. The cells were subjected to short tandem repeat classification recommended by ATCC.

LentiCRISPR construction

CRISPR-Pool KOUT products from GeneChem were prepared using the GeCKO plasmid library constructed by the Zhang Feng laboratory at the Broad Institute. We used the Zhang Feng (GeCKO v.2) plasmid library, which included 123,411 single-guide RNAs (sgRNAs) that targeted 19,050 protein-coding genes (six sgRNAs per gene), 1,864 microRNAs (four sgRNAs per microRNA), and approximately 1,000 nontargeting control sgRNAs.

Briefly, for each virus, the lentiviral plasmid and packaging constructs (pHelper 1.0 and pHelper 2.0) were cotransfected into HEK293T cells grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Shanghai Micronas Biochemicals Co., Ltd., Shanghai, China), followed by incubation in the presence of 5% CO₂ at 37°C for 60 h. Next, 1% bovine serum albumin (Sigma) was added to improve virus stability.

Based on the cell state, supernatant from 293T cells was collected 24 and 48 h after transfection and stored at 4°C. The fluid was then suction-filtered and passed through a tangential flow filtration system. The sample was further purified using an AKTA ion-exchange chromatography system, packaged into ultrafiltration centrifuge tubes, and centrifuged at 4°C and 5500 rpm. The duration of each centrifuge cycle was adjusted according to the rate of virus concentration, until the target volume was achieved. Through these methods, we designed a single lentiviral vector to deliver Cas9 sgRNA and a puromycin selection marker to the target cells (lentiCRISPR).

Cytotoxicity assay

We used a Cell Counting Kit-8 (CCK-8) assay to assess cell viability. Cells were seeded in 96-well plates at a density of 2 × 10³ cells/well. Next, 10 μL of CCK-8 solution was added into each well at the indicated time. After incubation for 4 h at 37°C in a humidified atmosphere containing 5% CO₂, the optical density (OD) value was recorded at 450 nm using a microplate reader (Bio-Rad, Richmond, VA, USA). The experiment was performed in triplicate.

Cell count assays

Cells were plated at a density of 20% and then treated with the target drugs. When the control cells reached a density of approximately 80%, cell counting was performed using a Cell counter (Nexcelom, Bioscience LLC, Lawrence, MA, USA). Cells were counted at least four times for each treatment at each time.

Statistical analysis

Calculation of the half-maximal inhibitory concentration (IC₅₀) was performed using GraphPad Prism5 Software, and gene ontology (GO)
CRISPR-Cas9 knockout screening for gene identification

Table 2. Cell growth conditions under different drug concentrations

<table>
<thead>
<tr>
<th>Drug concentration (ng/mL)</th>
<th>Multiplicity of infection</th>
<th>Cell inhibition rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1438.2428</td>
<td>0.00</td>
</tr>
<tr>
<td>0.5</td>
<td>1348.0105</td>
<td>6.27</td>
</tr>
<tr>
<td>1.0</td>
<td>1233.936</td>
<td>14.21</td>
</tr>
<tr>
<td>2.0</td>
<td>1102.5219</td>
<td>23.34</td>
</tr>
<tr>
<td>4.0</td>
<td>372.2468</td>
<td>74.12</td>
</tr>
<tr>
<td>6.0</td>
<td>0</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Results

Multiplicity of infection

In the pre-experiment, the lentivirus multiplicity of infection (MOI) was measured and determined by the functional MOI value (Table 1; Figure 1). When the MOI was 0.5 or 1, both the groups showed functional MOIs close to 0.4. Thus, to ensure that cells were only infected with one virus, we used an MOI of 0.5 for the actual experiment.

Determination of the PTX concentration

Next, we evaluated the optimal concentration of PTX for treating the cells. The concentration on a semi-logarithmic plot was found to be 8.789 ng/mL. We then evaluated the appropriate concentration for achieving growth inhibition of SiHa cells. Our results indicated that 3 ng/mL was the optimal concentration (Table 2; Figure 2).

Screening of candidate genes whose loss contributed to sensitivity to PTX

To identify genes whose loss induced sensitivity to PTX, the cells were treated with PTX or the vehicle dimethylsulfoxide for 0-14 days and then subjected to high-throughput sequencing (Figure 3).

Compared with vehicle-treated cells, the sgRNA frequency distribution in PTX-treated cells changed under PTX-selected pressure in two
We selected genes whose loss sensitized SiHa cells to PTX by satisfying the filter criteria (Table 3). A total of 101 deleted genes were selected after 7 days, and 374 genes were selected after 14 days. The FC was determined by comparing the frequencies at 7 and 14 days with that at 0 days. The Bayes factor was also calculated for each gene [12].

GO and KEGG pathway analyses

Using GO analysis, we identified the functions of the target genes. The functions were ranked by gene set enrichment analysis [13] (F-test, Bonferroni-corrected P < 0.05; Figure 4A, 4B). The results revealed that the deleted genes play a role in NF-kB signaling. It also revealed some pathways, such as oxidative phosphorylation, ubiquitin-mediated proteolysis, RARRXR pathway, and cytokine receptor interaction, which have not been studied before.

Discussion

In this study, we used the Cas9 system to explore the genes associated with sensitivity to PTX in cervical cancer for the first time. Among the depleted genes under selective pressure, we identified ABCC9, which belongs to the ABC transporter gene family, related to multidrug transport. We also selected representative genes previously shown to participate in regulating cancer cell reactivity to chemotherapy.

Of the genes obtained as hits on our screen, IL-37 has been reported to be involved in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [14]. Moreover, EIF3C and PPP2R5B play a role in the mammalian target of rapamycin (mTOR) pathway [15-17]. mTOR, the downstream target of the PI3K/Akt pathway, is critical for tumor cell proliferation, growth, differentiation, metabolism and apoptosis [18]. Recent studies have shown that human papilloma virus oncogenes E6/E7/E5 activate the PI3K/Akt/mTOR signaling pathway, which modulates tumorigenesis and progression [19]. Moreover, high mTOR expression is associated with chemoresistance in cervical cancer [20]. Other studies have shown that Akt and mTORC1 signaling mediates resistance to PTX by protecting cancer cells from death/apoptosis [21, 22]. Furthermore, previous reports have shown that PI3K, Akt and mTOR inhibitors upregulate sensitivity to various conventional chemotherapeutic agents [23-25]. These results explain the mechanisms and pathways through which the loss of IL-37 increased PTX sensitivity in our study. We also identified AKT1S1, a component of mTORC1 [26], as a gene related to drug sensitivity, further highlighting the role of the mTOR pathway in affecting PTX sensitivity.

MAPK37 belongs to the MAP3K family, which is the dominant member of the mitogen-activated protein kinase (MAPK) signaling pathway [27]. In addition, some of the identified deleted genes, PPP1R7, PPP2R5B, PPP1R7 and PPP1R11, belong to the phosphoserine/threonine phosphatase (PPP) family and have been proven to regulate the MAPK signaling pathway [17, 28, 29]. MAPK pathways are activated by diverse extracellular and intracellular stimuli, including peptide growth factors, cytokines, hormones, and various cellular stressors, such as oxidative stress and endoplasmic reticulum stress. These signaling pathways regulate various cellular activities, including proliferation, differentiation, survival and death [30]. The anticancer effects of PTX can be partly attributed to apoptosis, which is mediated by multipolar spindles. Thus, apoptosis contributes to PTX sensitivity, and many studies have shown that changes in the apoptosis pathway result in relative sensitivity or resistance to PTX [31, 32]. The MAPK pathway plays an important role in apoptosis [33] and mediates the variability PTX sensitivity [34]. So, loss of these genes contributes to PTX sensitivity.

The mTOR signaling pathway and the MAPK pathway have a common target: 4EBP. However, these two routes have opposing roles in determining PTX therapeutic efficacy (Figure 5).

Cas9 technology provides a reliable method for exploring the essential factors affecting the degree of PTX sensitivity at the gene level. In most traditional in vivo studies, RNA interfer-

Table 3. Candidate gene screening conditions

<table>
<thead>
<tr>
<th>#</th>
<th>Screening method</th>
<th>Day 7 versus day 0</th>
<th>Day 14 versus day 0</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$</td>
<td>FC_{DMSO}</td>
<td>&lt; 2 &amp; FC_{Paclitaxel} &lt; -2$</td>
</tr>
<tr>
<td>2</td>
<td>$BF_{DMSO} &lt; 0 &amp; BF_{Paclitaxel} &gt; 2$</td>
<td>461</td>
<td></td>
</tr>
</tbody>
</table>
CRISPR-Cas9 knockout screening for gene identification

RNA interference (RNAi) is the main method for gene knock-out. However, in this study GeCKO screening was shown to provide an effective alternative to RNAi. First, RNAi reduced protein expression at the RNA level, whereas GeCKO targeted DNA. Cas9 could be programmed to induce a loss-of-function allele at specific genomic loci \[19, 35, 36\], which yielded high screening sensitivity. Second, the RNAi knockout zone only applied to transcripts, whereas Cas9 could target the entire gene range, including promoters, enhancers, introns and intergenic regions. Moreover, in previous studies, cancer cells associated with chemoresistance were routinely derived from patients who appeared chemoresistant in the clinical setting or from cell lines treated with chemotherapeutic agents for several days \[37, 38\], and changes in gene expression were then analyzed. In contrast, in our study, the Cas9 system provided genome-wide knockout in chemo-naïve cells within a short period of time, avoiding additional gene mutations acquired during therapeutic intervention and prolonged culture. These factors support the reliability of the Cas9 system.

In summary, we identified novel candidate genes associated with sensitivity to PTX in cervical cancer using CRISPR-Cas9 to induce their deletion. However, this was an in vitro study, and the dosage and frequency of PTX are different from those in the clinical setting. Therefore, moving ahead, we need to conduct large sample clinical trials to develop related drugs considered more effective therapeutic options for patients with cervical cancer.

Acknowledgements

This study was supported by grants from Beijing Municipal Science and Technology Commission (D131100005313009) and the Special Program for Development of Clinical Medicine of Beijing Municipal Administration of Hospitals (ZYLX2017S).

Disclosure of conflict of interest

None.
CRISPR-Cas9 knockout screening for gene identification

Address correspondence to: Yu-Mei Wu, Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 17 Qihelou St, Dongcheng District, Beijing 100006, China. E-mail: wym597118@163.com

References

CRISPR-Cas9 knockout screening for gene identification


